"Brodalumab Viable Option for Psoriasis Across Racial, Ethnic Subgroups" - Abigail Sutton
Senior author Andrew Alexis, MD, PhD, director of the Skin of Color Center at Mount Sinai and chair of the department of dermatology at Mount Sinai St. Luke’s and Mount Sinai West discusses his most recent psoriasis study. According to Dr. Alexis, brodalumab was associated with skin clearance in the treatment of moderate to severe plaque psoriasis across various subgroups defined by race or ethnicity. Patients were randomly assigned to brodalumab or ustekinumab with the first dose followed by a second dose four weeks later and then doses every 12 weeks, or a placebo was giving during the 12-week induction phase. He added, “Because of the unique manifestations of psoriasis symptoms in patients with skin of color, specific analyses evaluating the efficacy, safety and health outcomes of therapies for psoriasis in patients with skin of color are needed.”
— Andrew Alexis, MD, MPH, Associate Professor, Dermatology, Icahn School of Medicine at Mount Sinai, Director, The Skin of Color Center at Mount Sinai, Site Chair, Department of Dermatology, Mount Sinai St. Luke’s-Mount Sinai West
New Insights Revealed On Tissue-Dependent Roles of JAK Signaling in Inflammation
Dec 21, 2023 View All Press Releases
New RNA-based Therapy Combats Melanoma in Mouse Models
Jul 27, 2023 View All Press Releases
New Treatment for Moderate to Severe Atopic Dermatitis Shows Promising Long-Term Results
Dec 09, 2022 View All Press Releases